NVision Imaging recently closed a $30 million funding round, as well as an additional $19.5 million from the German government.
The MRI agent developer will use the money to boost the development and marketing of NVision Polarizer, which is based on the parahydrogen-induced polarization technique, it said.
The funding round was led by Playground Global, with participation by return investors b-to-v and new participation from Pathena Investments, Entree Capital, the Lauder Family, ES Kapital, and Ulm Kapital.
NVision's quantum metabolic polarizers are planned for preclinical use in 2023.
